European Psychiatry - Volume 33 - March 2016

673 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S669
EV1001
The practitioner cope with adverse
events on atypical antipsychotics:
About 63 patients with schizophrenia
I. Berrahal ∗, R. Triki , R. Chebbi , B. Ghanjati , R. Ghachem
1 Razi Hospital, Pinel, Mannouba, Tunisia
2 Centre Hospitalier Universitaire Vaudois, Médecine et psychiatarie
pénitentiaires, Lausanne, Switzerland
∗ Corresponding author.
Introduction The propensity of atypical antipsychotics (AAP) for
having a therapeutic effectwith fewer side effects and the balancing
of these supposed benefits with tolerance are the subject of many
studies.
Aims and objectives We focused on adverse drug events (ADEs),
occurred under AAP, in a population of patients with schizophrenia
to assess the prevalences and describe how the practitioner deal
with these ADEs.
Methods We have used a retrospective and descriptive study of
63 Tunisian patients with schizophrenia, consulting in the adult
outpatient of Razi hospital and treated by one type of AAP. The study
periodwas 6 months from the 1st January 2015. We used the Birch-
wood Insight Scale (BIS), Positive and Negative Syndrome Scale
(PANSS) and Udvalg for Kliniske Undersogelser (UKU) to assess the
insight, psychotic symptoms and ADEs.
Results Twenty-four patients were on risperidone, 22 on olanza-
pine, 8 on amisulpride and 9 on clozapine. Antiparkinsonism drug
(15.9%)was associated because of neurological ADEsmainly Parkin-
sonism. Asthenia had a prevalence of 20.6%. Hypersalivation and
palpitation were estimated at 7.9% both. Weight gain’s prevalence
was 25.4%, including 1 case associated with hypercholesterolemia
and 1 case of unbalanced non-insulin-dependent diabetes. The
erectile dysfunction’s prevalence was 36.3% and decreased libido
27%. There were 2 cases of neutropenia and thrombocytopenia. The
management of these ADEs was observed when they moderately
began to influence the patient’s daily activity.
Conclusion ADEs must be subject to an appropriate treatment
and if necessary resort to a specialist consultation to confirm or
deny imputability to AAP.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1002
Do I need treatment? Insight and
therapy adherence in a group of
patients in treatment with
aripiprazole long acting injectable
S. Berta ∗, C. Víctor , T. Ivan , M. Julia , O. Silvia , C. Sandra ,
M. Estanislao , M. Luis Miguel , B. Noelia
1 Parc de Salut Mar, INAD, Hospital del Mar, Barcelona, Spain
2 Parc de Salut Mar, INAD, Barcelona, Spain
3 Parc de Salut Mar, INAD-CSMA, Santa Coloma de Gramanet, Spain
4 Parc de Salut Mar, INAD-CSMA, Barcelona, Spain
5 Parc de Salut Mar, INAD-CAEM, Santa Coloma de Gramanet, Spain
∗ Corresponding author.
Introduction Relapse prevention is one of the major goals in
psychiatry because it will mark the prognosis and quality of life
in patients. In this aspect, plays a very important role insight
and adherence to treatment. Some studies show that long acting
injectable treatments improve adherence as compared with oral
medications.
Objective The objective of this study is to analyse the degree of
insight and adherence to treatment of a group of patients with
aripiprazole long acting injectable ALAI treatment.
Methodology Descriptive study in a group of patients treated
with ALAI. Three months of follow-up. To assess the insight we had
use the 3 first items of the Unawareness of Mental Disorder SUMD.
Adherence to treatment is evaluated bymonitoring if patients come
to administrate ALAI.
Results n= 6, 2 women (33.3%) and 4 men (66.7%). The mean
age of the sample was 37 years. Diagnoses were 4 patients with
psychotic disorder (66.7%;) 2 with bipolar disorder (33.3%). At the
SUMD, mean score for the items consciousness of having a disor-
der and awareness of the effects of medication was 3, and for the
item awareness of the social consequences of mental disorder 4.
The mean score for the total punctuation was 10. Five (83.3%) had
a 100% of adherence, just 1 patient discontinued de treatment on
the third month.
Conclusions On our sample adherence, it was almost complete
in all patients. To highlight the scores for SUMD which means low
insight. A large sample is required to increase the reliability of the
study.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1003
Assessing quality of life following
long-acting injection treatment: 4
cases register
C.M. Calahorro ∗, M. Guerrero Jiménez , J.C. Navarro Barrios
Hospital Santa Ana, Unidad de Salud Mental, Motril, Spain
∗ Corresponding author.
Introduction Quality of life is defined by the World Health Orga-
nization as “Individuals’ perceptions of their position in life in the
context of the culture and value systems in which they live, and
in relation to their goals, expectations, standards, and concerns.”
Schizophrenia is a severe, disabling, lifelong disorder, associated
with severe social and occupational dysfunction. Aripiprazole Long
Acting Injection (LAI) is indicated for maintenance schizophre-
nia treatment in adult patients stabilised with oral aripiprazole.
It is the fourth second-generation antipsychotic depot formulation
approved for treating schizophrenia.
Objectives Assessing quality of life in 4 patients treatedwith arip-
iprazole LAI.
Methods In this paper, we evaluate of quality of life in 4 subjects
with diagnosis of paranoid schizophrenia (less 10 years of diagnos-
tic), male, age between 42 and 50 years, with poor adherence to oral
treatment. These patients received aripirazol LAI 400mg/month.
We evaluate quality of life at baseline and after 3 months. We
used the Quality of Life Scale (QOLS) and WHO-Quality of Life-Bref
(WHOQOL-BREF).
Results Results demonstrated significant greater improvements
in all QLS scores. No significant changes in theWHOQOL-BREF total,
but improvement in subscale scores.
Conclusion Quality of life in schizophrenia is adversely influ-
enced by the presence of clinical symptoms, especially negative
and depressive. Depot medications can improve treatment adher-
ence, however, long-term antipsychotic use can lead to irreversible
adverse effects (dyskinesias), which in some cases were reduced
by using newer antipsychotics (risperidone, paliperidone, aripipra-
zole). Aripiprazole LAI can be useful to improve quality of life.
Further methodologically robust studies are needed to generate
evidence-based conclusions.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.